Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates

  Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates   Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – December 16, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative…

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 Conference Call and Webcast To be Held Monday December 16, 2019 4:30pm Eastern Time NEW YORK – December 10, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for…

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint Abundance of Lachnospiraceae and Enterobacteriaceae Families as…